葵花药业：子公司盐酸非索非那定口服混悬液获得药品注册证书

Group 1 - The company announced that its subsidiary has received a drug registration certificate from the National Medical Products Administration for the oral suspension of Fexofenadine Hydrochloride [1] - The drug is classified as a Class 3 chemical drug and is a prescription medication [1] - The approved specifications for the drug are 120ml:0.72g, and it is indicated for alleviating symptoms of seasonal allergic rhinitis in children aged 2 years and older, as well as chronic idiopathic urticaria skin symptoms in children aged 6 months and older [1]